RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center, Suite 630
Bethesda
Maryland
20814
United States
Tel: 301-280-1992
Fax: 301-280-1996
Website: http://www.regenerx.com/
Email: info@regenerx.com
329 articles about RegeneRx Biopharmaceuticals, Inc.
-
RegeneRx Secures $1 Million in Funding
3/2/2018
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it entered into a Warrant Reprice Agreement whereby it received $1.03 million in warrant exercise proceeds.
-
Key U.S. Dry Eye Patent Issued to RegeneRx
2/22/2018
RegeneRx Biopharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued a patent for Thymosin beta 4 for use in the treatment of dry eye syndrome
-
RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
2/14/2018
RegeneRx, through its U.S joint venture, ReGenTree LLC, completed patient enrollment and treatment in its second Phase 3 clinical trial in approximately 600 patients with dry eye syndrome, reported positive clinical results, and has scheduled a meeting with the U.S. FDA in April 2018.
-
RegeneRx Biopharma Releases Annual Letter to Shareholders
12/11/2017
The letter is focused on updating shareholders on the Company's product development and commercial partnerships, clinical trials, fund-raising, and other operational plans over the next twelve months.
-
RegeneRx's Tβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium
11/16/2017
In his talk, Dr. Sosne presented data demonstrating Tβ4's important role in corneal wound healing at the benchtop and in his clinical experiences
-
RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial
10/31/2017
RegeneRx today announced the results of its phase III dry eye trial sponsored by its U.S. joint venture, ReGenTree, LLC.
-
RegeneRx Biopharmaceuticals, Inc. Receives Notice Of Allowance For Key Dry Eye Patent In U.S.
9/13/2017
-
RegeneRx Biopharmaceuticals, Inc. Completes License Expansion For RGN-137 In Europe, S. Korea, Japan, Canada And Australia
8/31/2017
-
RegeneRx Biopharmaceuticals, Inc. Collaborators Receive Notice Of 'Intent To Grant' EU Patent For The Treatment Of Peripheral Neuropathy
8/14/2017
-
RegeneRx Biopharmaceuticals, Inc. Updates On RGN-259 Phase 3 Dry Eye Trial
7/27/2017
-
RegeneRx Biopharmaceuticals, Inc. Collaborators Receive Notice Of Allowance Of U.S. Patent For The Treatment Of Peripheral Neuropathy
6/13/2017
-
RegeneRx Biopharmaceuticals, Inc. JV Presents Results Of Phase IIb/III (ARISE-1) Dry Eye Trial At Association for Research in Vision & Ophthalmology 2017
5/9/2017
-
RegeneRx Biopharmaceuticals, Inc. Releases Annual Letter To Shareholders
3/13/2017
-
RegeneRx Biopharmaceuticals, Inc. Licensee Receives FDA Permission To Conduct A Phase III Trial Of RGN-137 For Epidermolysis Bullosa In U.S.
2/27/2017
-
RegeneRx Biopharmaceuticals, Inc. Receives Notice Of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4.
1/9/2017
-
RegeneRx Biopharmaceuticals, Inc. Receives Notice Of Intent To Grant Patent In EU For Treating Neural Injury With Thymosin Beta 4
12/16/2016
-
RegeneRx Biopharmaceuticals, Inc. Announces First Patients Enrolled In Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) With RGN-259
11/10/2016
-
RegeneRx Biopharmaceuticals, Inc. Receives Notice Of Allowance For Patent For Tß4 Eye Drop Formulation
11/3/2016
-
RegeneRx Biopharmaceuticals, Inc. Joint Venture Initiates Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome
9/30/2016
-
RegeneRx Biopharmaceuticals, Inc. To Present At Rodman & Renshaw 18th Annual Global Investment Conference
8/30/2016